These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20082492)

  • 21. Continuous improvement versus innovation: the case for sipuleucel-T.
    Tombal B
    Eur Urol; 2012 Apr; 61(4):648-9; discussion 650-1. PubMed ID: 22154024
    [No Abstract]   [Full Text] [Related]  

  • 22. Provenge: combating prostate cancer with a vengeance?
    Schwaab T; Pili R
    Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304
    [No Abstract]   [Full Text] [Related]  

  • 23. Citizenship in our profession.
    Droller MJ
    J Urol; 2010 Oct; 184(4):1248-50. PubMed ID: 20723933
    [No Abstract]   [Full Text] [Related]  

  • 24. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
    Goodman AJ
    J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunotherapy: a new option for advanced prostate cancer.
    Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869
    [No Abstract]   [Full Text] [Related]  

  • 26. How does sipuleucel-T alter our clinical practice?
    George D
    BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691
    [No Abstract]   [Full Text] [Related]  

  • 27. Sipuleucel-T (APC8015) for prostate cancer.
    So-Rosillo R; Small EJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Provenge Angst a symbol or symptom of the times?
    Holcombe DG
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial comment.
    Drake C
    Urology; 2013 Jun; 81(6):1302. PubMed ID: 23582480
    [No Abstract]   [Full Text] [Related]  

  • 30. Putting Provenge in perspective.
    Moul JW
    Oncology (Williston Park); 2011 Mar; 25(3):255, 258. PubMed ID: 21548468
    [No Abstract]   [Full Text] [Related]  

  • 31. Proposed mechanisms of action for prostate cancer vaccines.
    Geary SM; Lemke CD; Lubaroff DM; Salem AK
    Nat Rev Urol; 2013 Mar; 10(3):149-60. PubMed ID: 23399727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer.
    Brody H
    Nature; 2015 Dec; 528(7582):S117. PubMed ID: 26672779
    [No Abstract]   [Full Text] [Related]  

  • 33. David Urdal. Interview with Asher Mullard.
    Nat Rev Drug Discov; 2011 Oct; 10(11):806-7. PubMed ID: 22037031
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic cancer vaccine survives biotech bust.
    Ledford H
    Nature; 2015 Mar; 519(7541):17-8. PubMed ID: 25739610
    [No Abstract]   [Full Text] [Related]  

  • 35. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for prostate cancer: walk, don't run.
    Drake CG
    J Clin Oncol; 2009 Sep; 27(25):4035-7. PubMed ID: 19635998
    [No Abstract]   [Full Text] [Related]  

  • 37. Cancer immunotherapy.
    White RL; Amin A
    Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approval of provenge seen as first step for cancer treatment vaccines.
    Brower V
    J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267
    [No Abstract]   [Full Text] [Related]  

  • 39. Dendritic cell vaccine hits FDA roadblock.
    Morrow T
    Manag Care; 2007 Jun; 16(6):52-3. PubMed ID: 17682740
    [No Abstract]   [Full Text] [Related]  

  • 40. PSA-based vaccines for the treatment of prostate cancer.
    Madan RA; Gulley JL; Arlen PM
    Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.